The FDA has approved Kenvue's Tylenol with Naproxen, the first OTC fixed‑dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg). Kenvue says the product works in under 30 minutes and can provide pain relief for up to 12 hours. Eight clinical studies reportedly show better pain control with the combination versus each ingredient alone, and a March 2026 survey found about 75% of persistent‑pain sufferers dissatisfied with current options. The approval grants three years of market exclusivity and the product should arrive soon at major US retailers.
FDA Clears Kenvue’s Tylenol With Naproxen — First OTC Fixed‑Dose Acetaminophen/Naproxen Combo
The FDA approval grants Kenvue a three-year exclusivity period for the new OTC formulation. Credit: DC Studio / Shutterstock.com.
The US Food and Drug Administration (FDA) has approved Kenvue's Tylenol with Naproxen, the first over-the-counter (OTC) fixed‑dose combination of acetaminophen (650 mg) and naproxen sodium (220 mg). The product is intended to offer an accessible, non‑opioid pain‑relief option without a prescription.
Fast Onset and Longer Duration
Kenvue reports the combined formulation begins working in under 30 minutes and can provide relief for up to 12 hours by pairing the fast‑acting analgesic effects of acetaminophen with the longer‑lasting anti‑inflammatory action of naproxen sodium.
Clinical Evidence and Consumer Feedback
The company cited findings from eight clinical studies that compared the fixed‑dose combination with products containing either acetaminophen or naproxen sodium alone. Kenvue says the pooled results showed improved pain relief with the combined formulation versus each ingredient administered separately.
Kenvue also referenced its March 2026 Kenvue Pain Consumer Survey of 6,240 respondents, reporting that roughly 75% of people living with persistent pain were dissatisfied with currently available pain‑relief options.
Dr Rajesh Mishra, Chief Medical Officer at Kenvue: "This milestone reflects Tylenol's long‑standing commitment to translating rigorous clinical science into accessible, over‑the‑counter solutions. Tylenol with Naproxen offers fast onset, up to 12‑hour relief, and the established safety profiles of two non‑opioid ingredients in a single, fixed‑dose formulation."
Market Impact and Availability
The FDA approval grants Kenvue three years of exclusivity for this new OTC formulation. Tylenol with Naproxen is expected to appear soon on the shelves of major retailers across the United States.
Important Safety Note
Although both ingredients are widely used, acetaminophen and naproxen have distinct safety considerations. Consumers should follow label directions, avoid exceeding recommended doses, and consult a healthcare professional if they have liver disease, stomach ulcers, cardiovascular disease, kidney problems, or are taking other medications that may interact with NSAIDs or acetaminophen.
Originally reported by Pharmaceutical Technology, a GlobalData brand.
Help us improve.
